Amylin's Bittersweet FDA News

Amylin Pharmaceuticals (Nasdaq: AMLN  ) announced mixed messages from the FDA yesterday. The agency approved its pen device for delivering its diabetes drug SYMLIN, but rejected its application to increase SYMLIN's label to include patients using basal insulin.

The introduction of the prefilled syringe should make the drug more user-friendly and increase sales, but my guess is that the label expansion would have helped increase sales far more than an easier injection system ever could. SYMLIN is currently approved for use in patients that take mealtime insulin, but the expanded label would have allowed it to market the drug to more patients.

Expanding the treatment population might have enabled the company to get a marketing agreement from one of the bigger players in the diabetes market -- perhaps insulin maker Novo Nordisk (NYSE: NVO  ) , or Eli Lilly (NYSE: LLY  ) , which markets Amylin's other diabetes drug, BYETTA.

The FDA rejection is a bit surprising, given the rather stellar study results released last year. In the clinical trial, one in four patients taking SYMLIN achieved the composite set of goals -- including glucose control, insulin use, and weight loss -- compared to less than 10% taking basal insulin alone.

Amylin is keeping quiet about the contents of the "not approvable" letter and says only that it will initiate discussions with the FDA to clarify the issues. Unfortunately, that's not a lot for investors to go on, but I'd guess it has to do with the FDA being worried about the risks versus rewards of the drug, as the agency did with the first approval. Basal insulin users haven't progressed as far as mealtime users, so the FDA may be worried about SYMLIN's use in patients that aren't as bad off.

If I'm right, and the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Sure, the drug promotes weight loss, but if it can't be approved for diabetics, Amylin might also have problems getting it approved for use in obese patients. Investors might not have to wait too long to learn the answer -- results from a phase 2 trial are expected later this year, which should give a glimpse into the safety of the drug in obese patients.

More Foolishness to get your glucose levels under control:

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 537796, ~/Articles/ArticleHandler.aspx, 10/28/2016 3:05:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
LLY $76.16 Down -0.60 -0.78%
Eli Lilly and Co. CAPS Rating: ***
NVO $40.94 Up +0.70 +1.74%
Novo Nordisk CAPS Rating: *****